Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA: 688506)

Sichuan Biokin Pharmaceutical Co.,Ltd. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	4,268	403.96	1,005	154.22	47.2	246.78
Trading Asset Securities	1,633	-	-	-	197.54	-
Cash & Short-Term Investments	5,901	403.96	1,005	154.22	244.74	246.78
Cash Growth	832.52%	-59.79%	551.49%	-36.99%	-0.83%	252.75%
Accounts Receivable	92.56	137.85	267.92	134.95	226.49	309.08
Other Receivables	59.56	3.9	5.14	2.95	0.64	0.07
Receivables	152.12	141.75	273.06	137.9	227.13	309.16
Inventory	154.18	140.91	101.33	82.33	65.77	77.29
Other Current Assets	171.18	89.2	47.22	49.36	33.21	25.78
Total Current Assets	6,378	775.82	1,426	423.81	570.85	659
Property, Plant & Equipment	544.93	534.79	420.26	404.98	380.91	347.96
Other Intangible Assets	27.26	28	29.53	31.16	32.88	34.46
Long-Term Deferred Tax Assets	222.95	76.18	83.23	65.8	48.2	36.27
Long-Term Deferred Charges	3.55	1.82	1.79	1.16	0.67	0.94
Other Long-Term Assets	8.87	8.5	30.28	24.54	8.47	12.06
Total Assets	7,186	1,425	1,991	951.46	1,042	1,091
Accounts Payable	176.24	160.17	128.85	45.96	67.96	56.63
Accrued Expenses	278.81	257.88	244.81	139.81	204.43	244.42
Short-Term Debt	670.73	275.12	155.13	161.23	150.21	195.04
Current Portion of Long-Term Debt	271.53	174.37	30.47	0.02	-	-
Current Portion of Leases	33.64	46.13	68.82	24.23	-	-
Current Income Taxes Payable	255.22	0.01	4.96	1.54	10.31	7.37
Current Unearned Revenue	357.92	8.67	17.42	10.78	18.1	-
Other Current Liabilities	106.05	131.48	86.74	87.75	81.44	110.65
Total Current Liabilities	2,150	1,054	737.2	471.32	532.45	614.12
Long-Term Debt	169.9	183.92	239.96	50	-	-
Long-Term Leases	15.75	8.65	52.95	51.42	-	-
Long-Term Unearned Revenue	11.99	15.63	13.29	31.04	37.24	28.84
Long-Term Deferred Tax Liabilities	-	-	0.08	-	0.08	-
Other Long-Term Liabilities	9.36	11.19	14.05	15.81	20.14	19.51
Total Liabilities	2,357	1,273	1,058	619.61	589.91	662.46
Common Stock	401	401	401	360.9	360.9	115.94
Additional Paid-In Capital	861.2	858.69	858.55	14.17	14.07	253.11
Retained Earnings	3,557	-1,109	-328.45	-45.98	74.01	44.01
Comprensive Income & Other	8.98	1.13	2.79	2.76	3.1	5.12
Total Common Equity	4,829	151.87	933.89	331.85	452.08	418.18
Minority Interest	-	-	-	-	-	10.04
Shareholders' Equity	4,829	151.87	933.89	331.85	452.08	428.22
Total Liabilities & Equity	7,186	1,425	1,991	951.46	1,042	1,091
Total Debt	1,162	688.19	547.33	286.91	150.21	195.04
Net Cash (Debt)	4,739	-284.23	457.41	-132.69	94.53	51.74
Net Cash Growth	3811.98%	-	-	-	82.72%	-
Net Cash Per Share	11.83	-0.71	1.26	-0.37	0.27	0.13
Filing Date Shares Outstanding	401	401	401	360.9	344.56	386.54
Total Common Shares Outstanding	401	401	401	360.9	344.56	386.54
Working Capital	4,228	-278.01	689.14	-47.51	38.4	44.88
Book Value Per Share	12.04	0.38	2.33	0.92	1.31	1.08
Tangible Book Value	4,801	123.88	904.36	300.69	419.2	383.72
Tangible Book Value Per Share	11.97	0.31	2.26	0.83	1.22	0.99
Buildings	334.76	304.56	302.23	300.82	252.7	250.33
Machinery	583.93	554.25	439.83	419.75	363.73	343.12
Construction In Progress	26.02	81.37	67.21	18.18	76.71	21.32

Source: S&P Capital IQ. Standard template. Financial Sources.